Dura Substitute(GXQ)
硬膜代用材 この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。
23 件
直近 2025.01.22
43 件
0 件
1,402 件
分類情報
| Product Code | GXQ |
|---|---|
| デバイス名 | Dura Substitute 硬膜代用材 この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。 |
| デバイスクラス | クラス II |
| 21 CFR 規制番号 | 882.5910 |
| 審査区分 | 510(k)(市販前届出) |
| 医療専門分野 | 神経科 |
| 定義 | - |
| フラグ | インプラント機器 |
| AI分析 | 本品は、外科手術等で欠損または切除された硬膜を補填・置換するために用いられる硬膜代用材です。米国ではクラスIIに分類され、市販前届出(510(k))の手続きにより、既存の同等品との実質的同等性を示すことで市販が認められる審査区分に位置づけられています。 米国市場での動向 本製品は510(k)方式で審査されており、届出は累計約40件、直近5年でも約5件と継続的な申請があり、参入企業は約20社に上ります。不具合報告は累計約1,400件で、死亡36件を含み傷害の比率が高い内訳となっており、主な問題として材料の穿刺・穴あき(Material Puncture/Hole)、体液・出血の漏出(Fluid/Blood Leak)、効果不十分(Lack of Effect)が挙げられています。回収は累計約20件で、クラスIIが約15件を占め、クラスIの回収は確認されていません。直近5年では約5件の回収があり、最新の回収は2024年11月に開始されています。 この分析は公開データ(openFDA・JMDN 対応情報)をもとに AI が生成した参考情報です。市場データは2026年8月時点の集計に基づきます。 |
FDA のデバイスクラスは 3 段階(クラス I〜III)、日本の医療機器は 4 段階(クラス I〜IV)で分類されており、 1 対 1 では対応しません。 リスク区分の考え方が異なるため、参考情報としてご利用ください。
米国での回収・承認・不具合報告
米国回収
全 23 件| 回収番号 | クラス | 回収開始日 | 企業 | 理由 | ステータス |
|---|---|---|---|---|---|
| Z-0834-2025 GXQ | クラス II | 2024.11.22 | Cook Biotech, Inc. | Incorrect version of IFU was used rather than updated version; and incorrect expiration date was used on two of the products. | 対応中 |
| Z-0262-2025 GXQ | クラス II | 2024.09.26 | Integra LifeSciences Corp. | Out of specification endotoxin levels. | 対応中 |
| Z-2207-2023 GXQ | クラス II | 2023.06.13 | Medtronic Neurosurgery | Dura regeneration matrix may have out-of-specification endotoxin levels due to issues with in-process and finished goods endotoxin testing, which may present clinically with signs and symptoms of an acute inflammatory process, comparable to infection. | 対応中 |
| Z-0669-2022 GXQ | クラス II | 2021.12.13 | Collagen Matrix, Inc. | Outer packaging (outer pouch) is not sealed compromising sterility and result in potential risk of patient infection, which could lead to revision surgery | 終了 |
| Z-0668-2022 GXQ | クラス II | 2021.12.13 | Collagen Matrix, Inc. | Outer packaging (outer pouch) is not sealed compromising sterility and result in potential risk of patient infection, which could lead to revision surgery | 終了 |
| Z-1387-2016 GXQ | クラス II | 2015.12.08 | Synthes (USA) Products LLC | It was reported that the SYNTHECEL Dura Repair could adhere to various anatomical structures post implantation, which may expose patients to potential risks in the event a surgeon intends to temporarily apply and subsequently remove a SYNTHECEL implant. SYNTHECEL Dura Repair labeling and promotional material are being updated to clarify that SYNTHECEL is intended to remain in place and is not intended to be removed. | 終了 |
| Z-1386-2016 GXQ | クラス II | 2015.12.08 | Synthes (USA) Products LLC | It was reported that the SYNTHECEL Dura Repair could adhere to various anatomical structures post implantation, which may expose patients to potential risks in the event a surgeon intends to temporarily apply and subsequently remove a SYNTHECEL implant. SYNTHECEL Dura Repair labeling and promotional material are being updated to clarify that SYNTHECEL is intended to remain in place and is not intended to be removed. | 終了 |
| Z-1385-2016 GXQ | クラス II | 2015.12.08 | Synthes (USA) Products LLC | It was reported that the SYNTHECEL Dura Repair could adhere to various anatomical structures post implantation, which may expose patients to potential risks in the event a surgeon intends to temporarily apply and subsequently remove a SYNTHECEL implant. SYNTHECEL Dura Repair labeling and promotional material are being updated to clarify that SYNTHECEL is intended to remain in place and is not intended to be removed. | 終了 |
| Z-1384-2016 GXQ | クラス II | 2015.12.08 | Synthes (USA) Products LLC | It was reported that the SYNTHECEL Dura Repair could adhere to various anatomical structures post implantation, which may expose patients to potential risks in the event a surgeon intends to temporarily apply and subsequently remove a SYNTHECEL implant. SYNTHECEL Dura Repair labeling and promotional material are being updated to clarify that SYNTHECEL is intended to remain in place and is not intended to be removed. | 終了 |
| Z-1383-2016 GXQ | クラス II | 2015.12.08 | Synthes (USA) Products LLC | It was reported that the SYNTHECEL Dura Repair could adhere to various anatomical structures post implantation, which may expose patients to potential risks in the event a surgeon intends to temporarily apply and subsequently remove a SYNTHECEL implant. SYNTHECEL Dura Repair labeling and promotional material are being updated to clarify that SYNTHECEL is intended to remain in place and is not intended to be removed. | 終了 |
| Z-0339-2014 GXQ | クラス II | 2013.10.28 | Synovis Surgical Innovations, Inc. | Synovis, a subsidiary of Baxter International Inc., is recalling certain shipments of VASCUGUARD and DURA-GUARD because Synovis, a subsidiary of Baxter International Inc., is recalling certain shipments of VASCUGUARD and DURA-GUARD because the shipping configurations in which the 6 fluid ounce units containing a specific revision of the Instructions for Use (IFU) shipped in a divided cell shipping | 終了 |
| Z-1300-2013 GXQ | クラス II | 2013.03.28 | Integra LifeSciences Corporation | Due to the process deviation, product lots in question may have been released with higher levels of pyrogens than permitted by the specifications for the products. | 終了 |
| Z-1285-2013 GXQ | クラス II | 2013.03.28 | Integra LifeSciences Corporation | Due to the process deviation, product lots in question may have been released with higher levels of pyrogens than permitted by the specifications for the products. | 終了 |
| Z-1284-2013 GXQ | クラス II | 2013.03.28 | Integra LifeSciences Corporation | Due to the process deviation, product lots in question may have been released with higher levels of pyrogens than permitted by the specifications for the products. | 終了 |
| Z-1283-2013 GXQ | クラス II | 2013.03.28 | Integra LifeSciences Corporation | Due to the process deviation, product lots in question may have been released with higher levels of pyrogens than permitted by the specifications for the products. | 終了 |
| Z-1282-2013 GXQ | クラス II | 2013.03.28 | Integra LifeSciences Corporation | Due to the process deviation, product lots in question may have been released with higher levels of pyrogens than permitted by the specifications for the products. | 終了 |
| Z-1081-2010 GXQ | - | - | - | - | - |
| Z-0588-04 GXQ | - | - | - | - | - |
| Z-0454-2011 GXQ | - | - | - | - | - |
| Z-0453-2011 GXQ | - | - | - | - | - |
510(k)(市販前届出)
全 43 件| No. | 番号 | 機器名 | 申請者 | 決定日 | 種別 | 概要 |
|---|---|---|---|---|---|---|
| 1 | K251191 | Collagen Dura Regeneration Membrane - Repair | Collagen Matrix, Inc. | 2025.11.18 | 通常(Traditional) | |
| 2 | K250420 | Helios Dura Regeneration Matrix | Helios Biomedical, Inc. | 2025.05.14 | 通常(Traditional) | |
| 3 | K223445 | ArtiFascia | Nurami Medical , Ltd. | 2023.08.10 | 通常(Traditional) | |
| 4 | K212943 | SyntheCel Dura Repair | Synthes (USA) Products, LLC | 2022.01.28 | 通常(Traditional) | |
| 5 | K183513 | XenoSure Dura Biologic Patch | LeMaitre Vascular, Inc. | 2019.06.13 | 通常(Traditional) | |
| 6 | K172603 | Cerafix Dura Substitute | Acera Surgical, Inc. | 2017.11.27 | 通常(Traditional) | |
| 7 | K163456 | DuraGen Secure Dural Regeneration Matrix | Integra LifeSciences Corporation | 2017.01.06 | 特別(Special) | |
| 8 | K161370 | Durepair Dura Regeneration Matrix | Medtronic Neurosurgery | 2016.11.02 | 通常(Traditional) | |
| 9 | K161278 | Cerafix Dura Substitute | Acera Surgical, Inc. | 2016.08.08 | 通常(Traditional) | |
| 10 | K153613 | Cerafix Dura Substitute | Acera Surgical, Inc. | 2016.03.16 | 通常(Traditional) | |
| 11 | K150825 | Collagen Dural Regeneration Matrix | Collagen Matrix, Inc. | 2015.11.20 | 通常(Traditional) | |
| 12 | K152481 | DURAFORM Dural Graft Implant | Codman & Shurtleff, Inc. | 2015.10.30 | 特別(Special) | |
| 13 | K141608 | COLLAGEN DURA MEMBRANE | Collagen Matrix, Inc. | 2015.01.16 | 通常(Traditional) | |
| 14 | K132850 | BOVINE PERICARDIUM SUTURABLE DURAL GRAFT, TUTOPATCH DM GRAFT, TUTOPLAST BOVINE PERICARDIUM DM | Rti Surgical, Inc. | 2014.03.31 | 通常(Traditional) | |
| 15 | K131792 | SYNTHECEL DURA REPAIR, SYNTHECEL DURA ONLAY | Synthes, Inc. | 2013.12.16 | 通常(Traditional) | |
| 16 | K131015 | BIODESIGN ONLAY DURAL GRAFT OR BIODESIGN DURAPLASTY GRAFT | Cook Biotech, Inc. | 2013.10.08 | 通常(Traditional) | |
| 17 | K122791 | LYOPLANT ONLAY | Aesculap, Inc. | 2013.06.04 | 通常(Traditional) | |
| 18 | K120600 | DURAGEN SECURE DURAL REGNERATION MATRIX | Integra Life Sciences | 2012.06.15 | 通常(Traditional) | |
| 19 | K113071 | SYNTHECEL DURA REPLACEMENT DEVICES | Synthes | 2012.01.09 | 通常(Traditional) | |
| 20 | K092388 | DURAGEN PLUS DURAL REGENERATION MATRIX- SPINAL MATRIX, MODEL DP2013SM, INTEGRA SPINAL MEND DURAL REGENERATION MATRIX, MO | Integra LifeSciences Corporation | 2010.01.21 | 通常(Traditional) |
出典の openFDA は各 510(k) の主要(primary)product code のみを収録しているため、副次コードを含む FDA 公式データベースの検索結果とは件数が異なる場合があります。 FDA 510(k) データベースで確認
PMA(市販前承認)
この product code の PMA 情報はありません。
不具合報告(MAUDE)トレンド
米国不具合報告検索で詳しく見る出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。
報告の存在は、機器と事象の因果関係を意味しません。報告件数を機器間の不具合発生率の比較に用いることはできません。
各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。
出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。
取得日: 2026.09.28
各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。